Polycystic kidney disease interventions

Jump to navigation Jump to search

Polycystic kidney disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polycystic kidney disease from other Diseases

Epidemiology and Demographics

Risk Factor

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Polycystic kidney disease interventions On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polycystic kidney disease interventions

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polycystic kidney disease interventions

CDC on Polycystic kidney disease interventions

Polycystic kidney disease interventions in the news

Blogs on Polycystic kidney disease interventions

Directions to Hospitals Treating Polycystic kidney disease

Risk calculators and risk factors for Polycystic kidney disease interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

There are no recommended therapeutic interventions for the management of [disease name].

OR

[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.

OR

[Name of intervention] is the mainstay of treatment for [disease or malignancy].

Indications

Dialysis is not the first-line treatment option for patients with polycystic kidney disease. Dialysis is usually reserved for patients with either:[1]

  • End stage renal disease (ESRD)
  • Renal failure

[Name of Intervention]

The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.

OR

[Name of intervention] is the mainstay of treatment for [disease or malignancy].

OR

The mechanism of [name of intervention] is as follows:

Contraindications

References

  1. Grantham JJ (October 2008). "Clinical practice. Autosomal dominant polycystic kidney disease". N. Engl. J. Med. 359 (14): 1477–85. doi:10.1056/NEJMcp0804458. PMID 18832246.

Template:WH Template:WS